- Hauptnavigation
- Navigation des Hauptbereiches
- Inhalt der Seite
Navigation des Hauptbereiches
Ausgewählte Publikationen Dr. Gerd Moldenhauer
Links
Tita-Nwa*, F., Moldenhauer*, G., Herbst, M., Kleist, C., Ho, A.D., and Kornacker, M. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol. Immunother. 56: 1911-1920, 2007. (*shared first authorship)
Popov, S.W., Moldenhauer, G., Wotschke, B., Brüderlein, S., Barth, T.F., Dorsch, K., Ritz, O., Möller, P., and Leithäuser, F. Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphoma. Cancer Res. 67: 6555-6564, 2007.
Moldenhauer, G., Popov, S.W., Wotschke, B., Brüderlein, S., Riedl, P., Fissolo, N., Schirmbeck, R., Ritz, O., Möller, P., and Leithäuser F. AID expression identifies interfollicular large B cells as putative precursors of mature B cell malignancies. Blood 107: 2470-2473, 2006.
Schmetzer, O., Moldenhauer, G., Riesenberg, R., Pires, J.R., Schlag, P., and Pezzutto, A. Quality of recombinant proteins determines the amount of autoreactivity detected against the tumor associated EpCAM antigen: low frequency of antibodies against the natural protein. J. Immunol. 174: 942-952, 2005.
Marmé, A., Strauß, G., Bastert, G., Grischke, E.-M., and Moldenhauer, G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int. J. Cancer 101: 183-189, 2002.
Schweizer, C., Strauß, G., Lindner, M., Marmé, A., Deo, Y.M., and Moldenhauer, G. Efficient carcinoma cell killing by activated polymorphonuclear neutrophils targeted with an Ep-CAMxCD64 (HEA125x197) bispecific antibody. Cancer Immunol. Immunother. 51: 621-629, 2002.
